Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACH Trial: Camzyos for Ischaemia in HOCM
NCT07120776Recruiting
- Sponsor
- The University of Manchester
- Start
- Mar 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mavacamten in Hypertrophic Obstructive Cardiomyopathy (HOCM), sponsored by The University of Manchester. Primary endpoint: Change in Myocardial Ischaemia at 12 months. Started Mar 2026; status: recruiting.
02
Drugs
mavacamten
03
Conditions
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Beyond the preview
Go deeper on NCT07120776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120776.